Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
CD83 Double Nickase Plasmid (h): sc-401864-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CD83 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- CD83 Double Nickase Plasmid (h) and CD83 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting CD83. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CD83 Antibody (D-3): sc-55536
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD83 Double Nickase Plasmid (h) | sc-401864-NIC | 20 µg | $410.00 |
CD83 encodes a type I transmembrane immunoglobulin superfamily glycoprotein that is rapidly induced during maturation of dendritic cells and is also expressed by activated B cells and subsets of T cells. CD83 contributes to antigen presentation and T cell priming by modulating immunological synapse formation, costimulatory signaling, and the stability and trafficking of surface immune receptors, intersecting with NF-κB–linked activation programs and cytokine-driven differentiation pathways. Through these roles, CD83 is commonly studied in contexts of immune tolerance, inflammatory signaling, and adaptive immune regulation. Altered CD83 expression and shedding patterns have been associated with immune dysregulation in autoimmunity, chronic inflammation, and tumor–immune interactions, supporting its use as a mechanistic marker in immunology research.
CD83 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the CD83 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within CD83. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt CD83 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of CD83-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.